Page 152 - Binder2

churn increases—payers are demanding not just
innovation, but reliability.
Not just molecules that work in trials, but therapies that
deliver consistent, long-term outcomes in the real world.

A biologic that works the first time—and keeps working—
is no longer a bonus.
It’s a precondition for future adoption.

So when we talk about sustainability, we’re talking about
more than just drug survival curves.
We’re talking about the ability of an entire class of
medicine to retain its relevance in the next era of
healthcare.

Because when the science gets harder…
When the patients get more complex…
When the system gets tighter…

Only the biologics that last will lead.

The Tools Are Already Here

This isn’t some speculative decade-away vision.

The science is here.
The platforms exist.
The delivery innovations are real.
What’s missing is alignment—a system that chooses to
reward what lasts, not just what launches.

And that choice begins with us.

150